Protara Therapeutics, Inc. — Director's Dealing 2014

Oct 21, 2014

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2014-10-21

Reporting Person: NOYES TIMOTHY P (Director, President & CEO)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1.905	2016-04-19	Common Stock (83742)		Direct
Stock Option (Right to Buy)	$2.381	2017-09-10	Common Stock (31505)		Direct
Stock Option (Right to Buy)	$3.174	2019-06-19	Common Stock (55829)		Direct
Stock Option (Right to Buy)	$3.174	2019-12-16	Common Stock (3479)		Direct
Stock Option (Right to Buy)	$1.270	2021-10-26	Common Stock (85388)		Direct
Stock Option (Right to Buy)	$4.920	2024-06-23	Common Stock (76732)		Direct
Stock Option (Right to Buy)	$4.920	2024-06-23	Common Stock (49291)		Direct
Stock Option (Right to Buy)	$10.00	2024-10-21	Common Stock (78818)		Direct

Footnotes

F1: The shares underlying these options are fully vested.

F2: This option is fully exercisable prior to its vesting, subject to a repurchase right held by the Issuer on the shares underlying this option that lapses (based on the original option vesting schedule) in equal quarterly installments over four years.

F3: This option is fully exercisable prior to its vesting, subject to a repurchase right held by the Issuer on the shares underlying this option that lapses (based on the original option vesting schedule) 25% on the first anniversary of the grant date and the remaining shares in equal quarterly installments over the next three years.

F4: The shares underlying this option vest in four equal installments annually over four years.

F5: Reflects a 1-for-15.87 reverse stock split effected on October 6, 2014.